临床合理用药杂志
臨床閤理用藥雜誌
림상합리용약잡지
CHINESE JOURNAL OF CLINICAL RATIONAL DRUG USE
2015年
18期
14-15,30
,共3页
平滑肌瘤%米非司酮%来曲唑%治疗结果
平滑肌瘤%米非司酮%來麯唑%治療結果
평활기류%미비사동%래곡서%치료결과
Leiomyoma%Mifepristone%Letrozole%Treatment outcome
目的:比较来曲唑与米非司酮治疗子宫肌瘤的临床疗效。方法选取2009—2013年曲阳仁济医院收治的子宫肌瘤患者135例,随机分为米非司酮组(62例)与来曲唑组(73例)。米非司酮组患者予以米非司酮治疗,来曲唑组患者予以来曲唑治疗。观察两组患者临床症状改善情况、子宫肌瘤体积、临床疗效、激素水平及不良反应发生情况。结果治疗前两组患者月经量增多、痛经、贫血、尿频尿急发生率比较,差异无统计学意义( P ﹥0.05);治疗后两组患者痛经、尿频尿急发生率比较,差异无统计学意义( P ﹥0.05),米非司酮组患者月经量增多、贫血发生率低于来曲唑组,差异有统计学意义(P ﹤0.05);米非司酮组患者子宫肌瘤体积小于来曲唑组(P ﹤0.05);米非司酮组患者临床疗效优于来曲唑组(P ﹤0.05);治疗前两组患者血清黄体生成素(LH)、促卵泡激素(FSH)、雌激素(E2)及孕酮(P)水平比较,差异无统计学意义(P ﹥0.05),治疗后米非司酮组患者血清 LH、E2、P 水平低于来曲唑组(P ﹤0.05),治疗后两组患者 FSH 水平比较,差异无统计学意义(P ﹥0.05);两组患者不良反应发生率比较,差异无统计学意义(P ﹥0.05)。结论米非司酮治疗子宫肌瘤的临床疗效显著,可改善患者临床症状,缩小子宫肌瘤体积,且不良反应小,安全性高。
目的:比較來麯唑與米非司酮治療子宮肌瘤的臨床療效。方法選取2009—2013年麯暘仁濟醫院收治的子宮肌瘤患者135例,隨機分為米非司酮組(62例)與來麯唑組(73例)。米非司酮組患者予以米非司酮治療,來麯唑組患者予以來麯唑治療。觀察兩組患者臨床癥狀改善情況、子宮肌瘤體積、臨床療效、激素水平及不良反應髮生情況。結果治療前兩組患者月經量增多、痛經、貧血、尿頻尿急髮生率比較,差異無統計學意義( P ﹥0.05);治療後兩組患者痛經、尿頻尿急髮生率比較,差異無統計學意義( P ﹥0.05),米非司酮組患者月經量增多、貧血髮生率低于來麯唑組,差異有統計學意義(P ﹤0.05);米非司酮組患者子宮肌瘤體積小于來麯唑組(P ﹤0.05);米非司酮組患者臨床療效優于來麯唑組(P ﹤0.05);治療前兩組患者血清黃體生成素(LH)、促卵泡激素(FSH)、雌激素(E2)及孕酮(P)水平比較,差異無統計學意義(P ﹥0.05),治療後米非司酮組患者血清 LH、E2、P 水平低于來麯唑組(P ﹤0.05),治療後兩組患者 FSH 水平比較,差異無統計學意義(P ﹥0.05);兩組患者不良反應髮生率比較,差異無統計學意義(P ﹥0.05)。結論米非司酮治療子宮肌瘤的臨床療效顯著,可改善患者臨床癥狀,縮小子宮肌瘤體積,且不良反應小,安全性高。
목적:비교래곡서여미비사동치료자궁기류적림상료효。방법선취2009—2013년곡양인제의원수치적자궁기류환자135례,수궤분위미비사동조(62례)여래곡서조(73례)。미비사동조환자여이미비사동치료,래곡서조환자여이래곡서치료。관찰량조환자림상증상개선정황、자궁기류체적、림상료효、격소수평급불량반응발생정황。결과치료전량조환자월경량증다、통경、빈혈、뇨빈뇨급발생솔비교,차이무통계학의의( P ﹥0.05);치료후량조환자통경、뇨빈뇨급발생솔비교,차이무통계학의의( P ﹥0.05),미비사동조환자월경량증다、빈혈발생솔저우래곡서조,차이유통계학의의(P ﹤0.05);미비사동조환자자궁기류체적소우래곡서조(P ﹤0.05);미비사동조환자림상료효우우래곡서조(P ﹤0.05);치료전량조환자혈청황체생성소(LH)、촉란포격소(FSH)、자격소(E2)급잉동(P)수평비교,차이무통계학의의(P ﹥0.05),치료후미비사동조환자혈청 LH、E2、P 수평저우래곡서조(P ﹤0.05),치료후량조환자 FSH 수평비교,차이무통계학의의(P ﹥0.05);량조환자불량반응발생솔비교,차이무통계학의의(P ﹥0.05)。결론미비사동치료자궁기류적림상료효현저,가개선환자림상증상,축소자궁기류체적,차불량반응소,안전성고。
Objective To compare the effect between letrozole and mifepristone in treating hysteromyoma. Methods A total of 135 patients with hysteromyoma were selected in Quyang Renji Hospital from January 2009 to December 2013,they were randomly divided into mifepristone group(62 cases)and letrozole group(73 cases). Mifepristone group were given mife-pristone treatment,letrozole group were given letrozole treatment. Improvement of clinical symptoms,hysteromyoma volume, clinical effect,hormone level and incidence of adverse reactions between the two groups were compared. Results Before treat-ment,incidence of menstrual dosage increased,dysmenorrhea,anemia,frequent micturition and precipitant urine showed no significant differences between the two groups(P ﹥ 0. 05),after treatment,incidence of dysmenorrhea,frequent micturition and precipitant urine showed no significant differences between the two groups(P ﹥ 0. 05),incidence of menstrual dosage in-creased,anemia of mifepristone group was lower than that of letrozole group(P ﹤ 0. 05);hysteromyoma volume of mifepristone group was less than that of letrozole group(P ﹤ 0. 05);clinical effect of mifepristone group was better than that of letrozole group(P ﹤ 0. 05);before treatment,luteinizing hormone( LH),follicle - stimulating hormone( FSH),estrogen( E2 ), progesterone(P)level showed no significant differences between the two groups(P ﹥ 0. 05),after treatment,LH,E2 ,P lev-el of mifepristone group were lower than those of letrozole group(P ﹤ 0. 05),FSH level showed no significant differences be-tween the two groups(P ﹥ 0. 05);incidence of adverse reactions showed no significant differences between the two groups(P﹥ 0. 05). Conclusion Mifepristone has notable curative effect in the treatment of hysteromyoma,can improve the clinical symptoms and reduce the hysteromyoma volume,has less adverse reactions and high safety.